Ultragenyx Pharmaceutical (RARE) Short Interest Ratio & Short Volume $28.44 +1.12 (+4.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$28.34 -0.11 (-0.37%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ultragenyx Pharmaceutical Short Interest DataUltragenyx Pharmaceutical (RARE) has a short interest of 8.80 million shares. This marks a 29.03% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.3, indicating that it would take 5.3 days of the average trading volume of 3.19 million shares to cover all short positions.Current Short Interest8,800,000 sharesPrevious Short Interest6,820,000 sharesChange Vs. Previous Month+29.03%Dollar Volume Sold Short$239.36 millionShort Interest Ratio5.3 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares94,540,000 sharesPercentage of Shares Shorted9.31%Today's Trading Volume2,239,592 sharesAverage Trading Volume3,190,304 sharesToday's Volume Vs. Average70% Short Selling Ultragenyx Pharmaceutical? Sign up to receive the latest short interest report for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRARE Short Interest Over TimeRARE Days to Cover Over TimeRARE Percentage of Float Shorted Over Time Ultragenyx Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20258,800,000 shares $239.36 million +29.0%N/A5.3 $27.20 6/30/20256,820,000 shares $247.98 million +12.2%7.6%5.3 $36.36 6/15/20256,080,000 shares $227.94 million +9.6%6.8%6 $37.49 5/31/20255,550,000 shares $187.98 million -5.8%6.4%5.9 $33.87 5/15/20255,890,000 shares $205.21 million +6.3%6.8%6.6 $34.84 4/30/20255,540,000 shares $215.95 million +1.5%N/A6.3 $38.98 4/15/20255,460,000 shares $192.96 million +20.5%6.3%6.6 $35.34 3/31/20254,530,000 shares $164.03 million -5.8%5.2%5.4 $36.21 3/15/20254,810,000 shares $189.23 million +4.8%5.5%5.7 $39.34 2/28/20254,590,000 shares $197.00 million +7.2%5.3%5.4 $42.92 Get the Latest News and Ratings for RARE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 2/15/20254,280,000 shares $181.86 million +2.9%4.9%5.4 $42.49 1/31/20254,160,000 shares $179.00 million -2.1%N/A5 $43.03 1/15/20254,250,000 shares $174.17 million +5.7%N/A4.8 $40.98 12/31/20244,020,000 shares $169.12 million +8.4%N/A5 $42.07 12/15/20243,710,000 shares $169.84 million +9.8%N/A5 $45.78 11/30/20243,380,000 shares $160.99 million +0.9%N/A4.8 $47.63 11/15/20243,350,000 shares $149.91 million +5.4%N/A4.7 $44.75 10/31/20243,180,000 shares $162.15 million +0.6%N/A4.5 $50.99 10/15/20243,160,000 shares $180.50 million +9.3%N/A4.7 $57.12 9/30/20242,890,000 shares $160.54 million -19.9%N/A4.1 $55.55 9/15/20243,610,000 shares $212.05 million +2.9%N/A4.7 $58.74 8/31/20243,510,000 shares $199.30 million -8.8%N/A4.1 $56.78 8/15/20243,850,000 shares $199.16 million -9.0%N/A4.3 $51.73 7/31/20244,230,000 shares $190.43 million -3.0%N/A4.8 $45.02 7/15/20244,360,000 shares $193.85 million +2.8%N/A5.1 $44.46 6/30/20244,240,000 shares $174.26 million -15.9%N/A4.8 $41.10 6/15/20245,040,000 shares $196.81 million +12.8%N/A6.2 $39.05 5/31/20244,470,000 shares $179.43 million +3.0%N/A6.1 $40.14 5/15/20244,340,000 shares $178.46 million -6.7%N/A5.9 $41.12 4/30/20244,650,000 shares $197.81 million +6.2%N/A6.3 $42.54 4/15/20244,380,000 shares $187.77 million +11.7%N/A6.3 $42.87 3/31/20243,920,000 shares $183.02 million +3.7%N/A5.3 $46.69 3/15/20243,780,000 shares $179.06 million -2.3%N/A5 $47.37 2/29/20243,870,000 shares $200.16 million +8.7%N/A4.9 $51.72 2/15/20243,560,000 shares $164.69 million +4.4%N/A4.6 $46.26 1/31/20243,410,000 shares $150.42 million -17.2%N/A4.3 $44.11 1/15/20244,120,000 shares $188.28 million +1.5%N/A4.4 $45.70 12/31/20234,060,000 shares $194.15 million +21.6%N/A4.1 $47.82 12/15/20233,340,000 shares $153.54 million +3.1%N/A3.4 $45.97 11/30/20233,240,000 shares $125.87 million -7.4%N/A3.4 $38.85One stock to replace Nvidia (Ad)Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.Click to get the full details on Eric Fry's "Nvidia alternative" right here. 11/15/20233,500,000 shares $136.78 million -15.9%N/A3.8 $39.08 10/31/20234,160,000 shares $147.26 million +24.6%N/A4.6 $35.40 10/15/20233,340,000 shares $112.12 million -15.0%5.0%4 $33.57 9/30/20233,930,000 shares $140.10 million +15.6%5.9%6.3 $35.65 9/15/20233,400,000 shares $128.11 million -1.5%5.1%6 $37.68 8/31/20233,450,000 shares $126.93 million -1.7%5.2%6.2 $36.79 8/15/20233,510,000 shares $134.75 million -1.1%5.3%6.2 $38.39 7/31/20233,550,000 shares $153.08 million -10.4%5.4%5.9 $43.12 7/15/20233,960,000 shares $174.95 million +6.5%6.0%6.4 $44.18 6/30/20233,720,000 shares $171.60 million +22.0%5.7%5.7 $46.13 6/15/20233,050,000 shares $149.02 million -4.1%4.7%4.5 $48.86 5/31/20233,180,000 shares $156.96 million -8.9%4.9%4.8 $49.36 5/15/20233,490,000 shares $171.08 million +17.1%5.3%5.5 $49.02 4/30/20232,980,000 shares $130.14 million +4.2%4.6%4.9 $43.67 4/15/20232,860,000 shares $109.25 million -8.0%4.4%4.8 $38.20 3/31/20233,110,000 shares $124.71 million +4.4%4.8%5.2 $40.10 3/15/20232,980,000 shares $121.38 million -3.3%4.6%5 $40.73 2/28/20233,080,000 shares $137.03 million -6.4%4.7%4.8 $44.49 2/15/20233,290,000 shares $145.45 million -3.2%5.1%4.8 $44.21 1/31/20233,400,000 shares $154.12 million -4.8%5.2%4.6 $45.33 1/15/20233,570,000 shares $155.47 million +6.3%5.5%4.7 $43.55 12/30/20223,360,000 shares $155.67 million -1.2%5.2%4.3 $46.33 12/15/20223,400,000 shares $154.94 million +14.1%5.2%4.2 $45.57 11/30/20222,980,000 shares $108.17 million -1.3%4.6%3.8 $36.30 11/15/20223,020,000 shares $107.09 million +2.0%4.7%4.1 $35.46 10/31/20222,960,000 shares $119.76 million -8.6%4.6%4.1 $40.46 10/15/20223,240,000 shares $120.07 million +5.9%5.0%4.5 $37.06 9/30/20223,060,000 shares $126.71 million -1.9%4.7%4.1 $41.41 9/15/20223,120,000 shares $147.51 million +6.5%4.8%4.5 $47.28 8/31/20222,930,000 shares $139.73 million -3.9%4.5%4.2 $47.69 8/15/20223,050,000 shares $156.16 million +7.4%4.7%4.4 $51.20 7/31/20222,840,000 shares $151.32 million -5.0%4.4%4.1 $53.28 7/15/20222,990,000 shares $193.60 million +3.5%4.6%4.6 $64.75 6/30/20222,890,000 shares $172.42 million +7.0%4.5%5.1 $59.66 6/15/20222,700,000 shares $136.92 million +0.4%4.2%4.9 $50.71 5/31/20222,690,000 shares $126.16 million -10.9%4.2%5.2 $46.90 5/15/20223,020,000 shares $155.44 million -1.3%4.7%6.2 $51.47 4/30/20223,060,000 shares $216.31 million +5.9%4.8%6.9 $70.69 4/15/20222,890,000 shares $246.81 million +2.5%4.5%6.7 $85.40 3/31/20222,820,000 shares $204.79 million -3.8%4.4%6.6 $72.62 3/15/20222,930,000 shares $186.61 million -3.3%4.6%7.1 $63.69 2/28/20223,030,000 shares $203.98 million -8.5%4.7%7.3 $67.32 2/15/20223,310,000 shares $243.45 million -4.9%5.2%7.6 $73.55 1/31/20223,480,000 shares $243.36 million -0.3%5.5%8.5 $69.93 1/15/20223,490,000 shares $251.45 million +0.6%5.5%8.5 $72.05 12/31/20213,470,000 shares $291.79 million -11.5%5.5%8.2 $84.09 12/15/20213,920,000 shares $325.56 million -1.3%6.2%9.2 $83.05 11/30/20213,970,000 shares $298.66 million -2.7%6.3%9.5 $75.23 11/15/20214,080,000 shares $328.60 million +10.3%6.5%10.6 $80.54 10/29/20213,700,000 shares $310.50 million -3.9%5.9%9.1 $83.92One stock to replace Nvidia (Ad)Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.Click to get the full details on Eric Fry's "Nvidia alternative" right here. 10/15/20213,850,000 shares $308 million -4.0%6.1%9.3 $80.00 9/30/20214,010,000 shares $361.66 million +3.9%6.4%9.7 $90.19 9/15/20213,860,000 shares $374.42 million -4.0%6.1%7 $97.00 8/31/20214,020,000 shares $387.09 million -0.7%6.4%6.7 $96.29 8/13/20214,050,000 shares $375.60 million -0.5%6.4%6.6 $92.74 7/30/20214,070,000 shares $324.91 million +3.0%6.5%6.6 $79.83 7/15/20213,950,000 shares $334.76 million +4.5%6.3%6.5 $84.75 6/30/20213,780,000 shares $360.42 million -23.6%6.0%6.3 $95.35 6/15/20214,950,000 shares $495.20 million -2.6%7.8%10.4 $100.04 5/28/20215,080,000 shares $516.69 million -1.0%8.0%11.6 $101.71 5/14/20215,130,000 shares $547.42 million -6.0%N/A12.1 $106.71 4/30/20215,460,000 shares $619.76 million +1.1%N/A12.4 $113.51 4/15/20215,400,000 shares $583.04 million -2.0%N/A13.1 $107.97 3/31/20215,510,000 shares $617.45 million -0.5%N/A12.1 $112.06 3/15/20215,540,000 shares $703.30 million -5.5%N/A11.2 $126.95 2/26/20215,860,000 shares $798.43 million +10.4%N/A11.6 $136.25 2/12/20215,310,000 shares $864.36 million -0.4%N/A10.9 $162.78 1/29/20215,330,000 shares $749.40 million -3.3%N/A11.3 $140.60 1/15/20215,510,000 shares $770.68 million -5.3%N/A10.1 $139.87 12/31/20205,820,000 shares $840.23 million -7.6%N/A11.3 $144.37 12/15/20206,300,000 shares $965.29 million -4.1%N/A14.2 $153.22 11/30/20206,570,000 shares $804.30 million -4.0%N/A15.4 $122.42 11/15/20206,840,000 shares $801.78 million -3.3%N/A16.4 $117.22 10/30/20207,070,000 shares $671.65 million -4.3%N/A17.4 $95.00 10/15/20207,390,000 shares $684.98 million +5.4%13.2%22.3 $92.69 9/30/20207,010,000 shares $576.15 million +1.7%12.5%20.3 $82.19 9/15/20206,890,000 shares $559.67 million +1.6%12.3%16.9 $81.23 8/31/20206,780,000 shares $576.71 million -0.9%12.1%15.7 $85.06 8/14/20206,840,000 shares $582.15 million -14.7%12.2%15.2 $85.11 RARE Short Interest - Frequently Asked Questions What is Ultragenyx Pharmaceutical's current short interest? Short interest is the volume of Ultragenyx Pharmaceutical shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 8,800,000 shares of RARE short. Learn More on Ultragenyx Pharmaceutical's current short interest. What is a good short interest ratio for Ultragenyx Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RARE shares currently have a short interest ratio of 5.0. Learn More on Ultragenyx Pharmaceutical's short interest ratio. Which institutional investors are shorting Ultragenyx Pharmaceutical? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ultragenyx Pharmaceutical: Jane Street Group LLC, Caption Management LLC, Persistent Asset Partners Ltd, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Ultragenyx Pharmaceutical's short interest increasing or decreasing? Ultragenyx Pharmaceutical saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 8,800,000 shares, an increase of 29.0% from the previous total of 6,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ultragenyx Pharmaceutical's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ultragenyx Pharmaceutical: Verona Pharma PLC American Depositary Share (4.77%), BridgeBio Pharma, Inc. (10.26%), Blueprint Medicines Corporation (5.95%), Roivant Sciences Ltd. (10.56%), Legend Biotech Corporation Sponsored ADR (4.57%), Elanco Animal Health Incorporated (4.75%), Regencell Bioscience Holdings Limited (9.57%), Revolution Medicines, Inc. (7.33%), Grifols, S.A. (0.96%), TG Therapeutics, Inc. (15.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Ultragenyx Pharmaceutical stock? Short selling RARE is an investing strategy that aims to generate trading profit from Ultragenyx Pharmaceutical as its price is falling. RARE shares are trading up $1.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ultragenyx Pharmaceutical? A short squeeze for Ultragenyx Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RARE, which in turn drives the price of the stock up even further. How often is Ultragenyx Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RARE, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies VRNA Short Interest Data BBIO Short Interest Data BPMC Short Interest Data ROIV Short Interest Data LEGN Short Interest Data ELAN Short Interest Data RGC Short Interest Data RVMD Short Interest Data GRFS Short Interest Data TGTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RARE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts